3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
33
Phase 1/2
12
Phase 2/3
5
Phase 3
3
Phase 1
2
Status
Completed
96
Unknown
57
Recruiting
53
Active not recruiting
35
Not yet recruiting
24
Terminated
18
Withdrawn
3
Suspended
2
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Gastrointestinal
3
Conditions
Stomach Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Motor Activity
1
Colonic Neoplasms
1
Carcinoma, Hepatocellular
1
Interventions
Cisplatin
22
Carboplatin
15
Radiotherapy
13
Paclitaxel
11
Gemcitabine
10
Rituximab
9
Fluorouracil
9
Drug Therapy
6
Dexamethasone
5
Cyclophosphamide
5
Capecitabine
5
Bevacizumab
5
Vinorelbine
4
Pemetrexed
4
Nivolumab
4
Methotrexate
4
Etoposide
4
Docetaxel
4
Bendamustine Hydrochloride
4
spartalizumab
3
pertuzumab
3
pembrolizumab
3
fludarabine
3
Vincristine
3
Trastuzumab
3
Surgical Procedures, Operative
3
Standard of Care
3
Prednisone
3
Oxaliplatin
3
Lenalidomide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
Withdrawn
×
Oxaliplatin
×
Clear all
NCT04488159
2024-09-20
iMAGINE
Medical University of Vienna
Phase 3
Withdrawn
NCT04859582
2021-12-16
KEYNOTE-859
Merck Sharp & Dohme LLC
Phase 3
Withdrawn
NCT01245582
2011-11-09
SECOX
Sanofi
Phase 3
Withdrawn